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ABSTRACT 
Renal toxicity in a 73 year old man using tenofovir/emtricitabine (TDF/FTC) as pre-exposure 
prophylaxis (PrEP) is described.  Reduced renal reserve, a higher exposure to co-medications 
and co-morbidities can present a challenge when assessing the risks and benefits of tenofovir 
based PrEP in the ageing population. 
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Pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC) available as the 
fixed drug combination Truvada, is highly effective in preventing HIV transmission [1-3] and 
is used increasingly as part of a combination prevention strategy in individuals at risk of 
acquiring HIV. A recent mathematical model showed the importance of PrEP as a single 
intervention able to outperform other isolated prevention strategies [4]. Tenofovir and 
emtricitabine were generally well tolerated although drug-related gastrointestinal side-effects 
were reported more frequently in the first 12 weeks by those receiving active PrEP [1-3]. A 
significant decline in creatinine clearance (CrCl) was observed in 3-18% of individuals [1-
3,5], with a more significant drop of CrCl (below 60mL/min) reported in 1% of patients. 
Following cessation of therapy, CrCl normalized [5]. In PROUD, 3/275 (1.1%) of the 
participants randomized to the immediate TDF/FTC arm interrupted drug due to elevated 
serum creatinine. Two had documented co-morbidities which may have influenced renal 
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
function; however, a relationship to TDF/FTC exposure could not be excluded. Renal 
dysfunction in the third case was attributed to recreational drug use [1]. 
  
We describe the challenge of managing a 73 year old homosexual man with pre-existing co-
morbidities, receiving daily TDF/FTC as PrEP and subsequently developing renal 
dysfunction requiring two isolated hospital admissions during follow-up. This man had a 
history of Crohn’s disease well controlled on mesalazine, and was randomized to immediate 
PrEP as part of the PROUD study in August 2014, following normal baseline serum 
creatinine level (78umol/L), with an estimated CrCl of 90mL/min (Cockcroft-Gault). No 
side-effects and full adherence to the medication were reported over the first 12 months 
following study entry although, after six months, a decline in MDRD estimated glomerular 
filtration rate (eGFR) was observed along with low level of proteinuria (≤1+) detected by 
urine dipstick. Serum creatinine and urine testing were increased in frequency to monitor for 
early signs of possible TDF-induced tubulopathy [6]. During the first 18 months, an eGFR 
<50mL/min was reported on two occasions (see full details in table 1). In October 2015 the 
patient experienced a suspected flare of his Crohn’s, manifested as profuse diarrhea and 
fatigue and resulting in significant dehydration and acute kidney injury (AKI). A rise in 
serum creatinine from 120 to 195umol/L and resultant drop in CrCl from 52 to 30mL/min 
were noted, along with severe hypokalemia (2.1mmol/L) without hypophosphataemia 
(0.94mmol/L). Following cessation of TDF/FTC, fluid resuscitation and treatment with 
intravenous antibiotics and potassium supplementation, renal function returned to baseline. 
Secondary tests were performed to investigate further the possible causes for renal 
dysfunction. A kidney ultrasound scan was unremarkable, whilst repeated urinary fractional 
excretion of electrolytes, showed normal values of fractional excretion of sodium, which fell 
below 1% during episode of AKI, suggesting dehydration as mechanism of renal failure. 
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During trial management group meetings it was agreed that the risk for the user to catch HIV 
outweighed the risk to his renal function, hence the clinicians concurred with the participant 
preference to continue on PrEP. Nevertheless, following a reoccurrence of AKI, triggered by 
another episode of persisting diarrhea, in December 2015 the clinical team decided not to 
prescribe any more PrEP. On this occasion creatinine levels rose again to 1.5 times their 
normal value and eGFR dropped down to 32 mL/min. After intravenous fluids correction the 
renal function returned to pre-AKI levels.  
This case describes an example of renal dysfunction in an older man with pre-existing co-
morbidities and co-medications on PrEP. It is known that people over 50 living with HIV are 
at a higher risk of clinical progression [7] and in 2014, approximately 6% of MSM newly 
diagnosed with HIV in the UK were over 50 years of age [8]. This data reinforce the validity 
of using PrEP in this selected population.  Only 9% (83/900) individuals in this age group 
were included in IperGAY and PROUD studies.  As a result, there are no solid data on the 
long term impact of PrEP in a HIV-negative population which is more prone to multiple co-
morbidities, polypharmacy and reduced renal function at baseline compared to younger 
counterparts. Also, onset of TDF-induced tubular dysfunction seems to correlate with older 
age in HIV positive patients [9]. UK national guidelines for PrEP are not yet available, but 
renal monitoring is advised in a position statement [10]. It is possible that cases similar to this 
one will become more frequent with wider availability of PrEP, suggesting the urgent need 
for additional PrEP options that are less renally toxic. Further data on the long term on renal 
monitoring of individuals with co-morbidities and aged >50 years is needed to establish the 
optimal frequency of testing.   
We encourage research on additional options for PrEP that are less renally toxic. A 
combination with tenofovir alafenamide and emtricitabine (TAF/FTC) has recently been 
licensed for treatment, and may shortly be evaluated for PrEP [11].  TAF showed less 
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detrimental effects on the kidneys and bones compared with TDF in HIV-positive patients 
[12].  Cabotegravir, a new long-acting injectable antiretroviral agent, showed significant 
protection in macaques [13], and there are plans to evaluate the efficacy in a non-inferiority 
design compared to TDF/FTC.  Due to favourable pharmacokinetics and promising 
preliminary in-vitro studies, maraviroc/lamivudine or raltegravir/lamivudine regimens [14] 
could be possible future options.   
In an ideal world, potential PrEP users would have a choice of agents to select and this choice 
could be individualized depending on age, co-morbidities and preference.   For now options 
are limited.  Subjects in the deferred arm of the PROUD study had a particularly high risk of 
catching HIV infection (HIV incidence = 9.0/100 person-years).  With this in mind, the 
balance of renal risk from daily tenofovir against a lifetime of infection with a nephrotoxic 
virus and need for lifelong medication favoured PrEP at baseline. With the emergence of 
repeated AKI, the risk-benefit balance in this participant shifted towards interruption and 
discontinuation of tenofovir based PrEP.  This needs to be clearly explained to individuals so 
that they can make an informed decision about the risks, up to the point that a drug becomes 
clinically contraindicated. 
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TABLE 1. Markers of renal function and kalemia over time   
Time 
(months) 
Baseline
° 
 
6  12  18  24 25 
† 
26  27  28  
† 
30  
Event  PrEP 
start 
    AKI 
followed 
by PrEP 
suspension 
PrEP 
restarted on 
Ipergay 
scheme 
 AKI 
followed by 
final PrEP 
suspension 
Post 
PrEP 
suspen
sion 
Creatini
ne 
(mmol/L) 
78 99 130 108 12
0 
195 116 112 180 105 
eGFR* 
(mL/min) 
90 65 47 59 52 30 54 56 32 60 
K+ 
(mEq/L) 
4.1 3.
4 
4.3 4.2 3.8 2.1 4.7 3.5 2.1 4.4 
 
°. 12/08/2014 
†.  Hospital admission 
*. Calculated calculated by the abbreviated MDRD equation 
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